2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…2016 American Transplant Congress
Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.
Background: Mycophenolate mofetil (MMF) is a highly effective immunosuppressive agent in transplant therapy. Although MMF is generally well tolerated, optimal therapy may be limited by…2016 American Transplant Congress
Do Powerful Induction Antibodies Increase Post Renal Transplant Infections?
Transplant Institute, Tulane University School of Medicine, New Orleans, LA.
Purpose: Infection is one of the most common and costly complications of solid organ transplantation. Alemtuzemab (AL) is a powerful antibody that significantly reduced rejection…2016 American Transplant Congress
Anti-Thymocyte Globulin Induced Thrombocytopenia and Bleeding After Kidney Transplantation.
Background: Bleeding is a significant challenge after renal transplantation. Anti-thymocyte globulin (ATG) induced thrombocytopenia may increase bleeding after kidney transplantation (KTx), but this association has…2016 American Transplant Congress
Diabetes Mellitus and Kidney Transplant Outcomes.
Background:This study investigates the impact of pre-existing (PDM) and new onset diabetes (NODAT) on the graft and patient survival after kidney transplant.Methods:The UNOS database was…2016 American Transplant Congress
The Incidence of Symptomatic Pericardial Effusion with Long-Term Sirolimus Therapy.
1Surgery, Albany Medical College, Albany, NY; 2Cardiology, Albany Medical College, Albany, NY.
BACKGROUNDSirolimus is an approved agent for immunosuppressive therapy after renal transplantation. Pericardial effusion and tamponade have been recognized as potentially serious complications of long-term sirolimus…2016 American Transplant Congress
Outcomes from De Novo Tacrolimus Weight-Based Dosing Compared to Conservative Dosing in Kidney Transplant Recipients.
Purpose: To compare de novo tacrolimus (TAC) weight based dosing (WDG) and conservative dosing (CDG) on incidence and duration of DGF in adult kidney transplant…2016 American Transplant Congress
Effect of Inflammation on Concentration of Intracellular Tacrolimus.
Background: The use of calcineurin inhibitors improved the outcome for transplant recipients. However, acute rejection (AR) and infection remained still an unsolved problem. We evaluated…2016 American Transplant Congress
Evaluation of the Utilization of Filgrastim in Kidney Transplant Recipients.
Purpose: Granulocyte colony-stimulating factors (G-CSF), such as filgrastim, stimulate the production, proliferation, and differentiation of neutrophils and are indicated for the treatment of neutropenia in…2016 American Transplant Congress
Social Support Does Not Predict Medication Adherence Post-Transplantation: A Systematic Review and Meta-Analysis.
Background: Although social support is used to determine eligibility, the relationship between social support and nonadherence remains unclear. We examined the predictive value of social…
American Transplant Congress abstracts